Skip to content

Evaluation of a Rapid Diagnostic Device, CL Detect, for the Diagnosis of Cutaneous Leishmaniasis in Tunisia

Evaluation of a Diagnostic Device, CL Detect Rapid Test, for the Diagnosis of Cutaneous Leishmaniasis in Tunisia

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01769612
Acronym
CL Detect™
Enrollment
168
Registered
2013-01-16
Start date
2013-01-31
Completion date
2014-04-30
Last updated
2017-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin Diseases, Parasitic

Keywords

Leishmaniasis, Leishmania

Brief summary

The purpose of the study is to evaluate the sensitivity and specificity of CL Detect, in subjects with suspected CL in Tunisia.

Detailed description

Subjects were selected based on clinical appearance of the skin lesion characteristics of cutaneous leishmaniasis (CL). Study compared the CL Detect Rapid Test vs microscopic identification of Leishmania amastigotes in a stained lesion sample. Two diagnostic samples were collected from the subjects lesion in the following order: 1) obtained with a dental broach for use with the CL Detect Rapid Test and 2) a second sample was obtained by scraping for use in the microscopic identification of amastigotes. Samples were analyzed by microscopy and CL Detect Repaid Test by different operators who evaluated each sample independently blinded to the other assay result.

Interventions

OTHERNo Intervention

Sponsors

InBios International, Inc.
CollaboratorINDUSTRY
Institut Pasteur of Tunis, Tunisia
CollaboratorUNKNOWN
U.S. Army Medical Research and Development Command
Lead SponsorFED

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* At least 18 years of age and generally healthy * Subject able to give written informed consent * Subject has a lesion suspicious for leishmaniasis that satisfies the following criteria for an index lesion: * less than 4 months in age * primarily ulcerative, ie not purely verrucous or nodular, and does not have clear clinical evidence of cellulitis * in a location suitable for collecting samples by dental broach, scraping, and aspiration * In the opinion of the investigator, the subject is capable of understanding and complying with the protocol

Exclusion criteria

• Received treatment for leishmaniasis within the last 2 months prior to signing consent, with the exception of mercurochrome

Design outcomes

Primary

MeasureTime frameDescription
Positive Result Comparison: CL Detect Rapid Test With Microscopy and Culture Resultswithin 1 hour after taking samplesComparison of CL Detect Rapid Test positive results with Microscopy and Culture results. Note: only data where results for all three methods were available were included in the analysis.

Countries

Tunisia

Participant flow

Recruitment details

168 subjects were enrolled in the regions of Sidi Bouzid and Gafsa, Tunisia

Participants by arm

ArmCount
CL Detect Rapid Test and Microsopy Samples
Samples taken to be evaluated in the CL Detect and Microscopy assays No Intervention
168
Total168

Baseline characteristics

CharacteristicCL Detect Rapid Test and Microsopy Samples
Age, Continuous40.2 years
STANDARD_DEVIATION 15.8
Lesion Age36.2 days
STANDARD_DEVIATION 22.6
Lesion Characteristics
Nobular
0 Participants
Lesion Characteristics
Secondary bacterial infection
74 Participants
Lesion Characteristics
Ulcerated
168 Participants
Lesion Location
Abdomen
0 Participants
Lesion Location
Arm
55 Participants
Lesion Location
Back of head
1 Participants
Lesion Location
Face
4 Participants
Lesion Location
Foot
35 Participants
Lesion Location
Hand
14 Participants
Lesion Location
Leg
59 Participants
Race/Ethnicity, Customized
North African
168 Participants
Region of Enrollment
Tunisia
168 participants
Sex: Female, Male
Female
93 Participants
Sex: Female, Male
Male
75 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 168
other
Total, other adverse events
0 / 168
serious
Total, serious adverse events
0 / 168

Outcome results

Primary

Positive Result Comparison: CL Detect Rapid Test With Microscopy and Culture Results

Comparison of CL Detect Rapid Test positive results with Microscopy and Culture results. Note: only data where results for all three methods were available were included in the analysis.

Time frame: within 1 hour after taking samples

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
CL Detect Rapid TestPositive Result Comparison: CL Detect Rapid Test With Microscopy and Culture Results147 Participants
MicroscopyPositive Result Comparison: CL Detect Rapid Test With Microscopy and Culture Results144 Participants
CulturePositive Result Comparison: CL Detect Rapid Test With Microscopy and Culture Results96 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026